Abstract
Cytochrome p450 (CYP) enzymes are predominantly involved in Phase 1 metabolism of xenobiotics. As only 6 isoenzymes are responsible for ∼90% of known oxidative drug metabolism, a number of frequently prescribed drugs share the CYP-mediated metabolic pathways. Competing for a single enzyme by the co-administered therapeutic agents can substantially alter the plasma concentration and clearance of the agents. Furthermore, many drugs are known to inhibit certain p450 enzymes which they are not substrates for. Because some drug-drug interactions could cause serious adverse events leading to a costly failure of drug development, early detection of potential drug-drug interactions is highly desirable. The ultimate goal is to be able to predict the CYP specificity and the interactions for a novel compound from its chemical structure. Current computational modeling approaches, such as two-dimensional and three-dimensional quantitative structure-activity relationship (QSAR), pharmacophore mapping and machine learning methods have resulted in statistically valid predictions. Homology models have been often combined with 3D-QSAR models to impose additional steric restrictions and/or to identify the interaction site on the proteins. This article summarizes the available models, methods, and key findings for CYP1A2, 2A6, 2C9, 2D6 and 3A4 isoenzymes.
Keywords: 3D-QSAR, Pharmacophore modeling, CYP1A subfamily, support vector machine (SVM), neural network
Current Topics in Medicinal Chemistry
Title: Computational Models for Predicting Interactions with Cytochrome p450 Enzyme
Volume: 6 Issue: 15
Author(s): Rieko Arimoto
Affiliation:
Keywords: 3D-QSAR, Pharmacophore modeling, CYP1A subfamily, support vector machine (SVM), neural network
Abstract: Cytochrome p450 (CYP) enzymes are predominantly involved in Phase 1 metabolism of xenobiotics. As only 6 isoenzymes are responsible for ∼90% of known oxidative drug metabolism, a number of frequently prescribed drugs share the CYP-mediated metabolic pathways. Competing for a single enzyme by the co-administered therapeutic agents can substantially alter the plasma concentration and clearance of the agents. Furthermore, many drugs are known to inhibit certain p450 enzymes which they are not substrates for. Because some drug-drug interactions could cause serious adverse events leading to a costly failure of drug development, early detection of potential drug-drug interactions is highly desirable. The ultimate goal is to be able to predict the CYP specificity and the interactions for a novel compound from its chemical structure. Current computational modeling approaches, such as two-dimensional and three-dimensional quantitative structure-activity relationship (QSAR), pharmacophore mapping and machine learning methods have resulted in statistically valid predictions. Homology models have been often combined with 3D-QSAR models to impose additional steric restrictions and/or to identify the interaction site on the proteins. This article summarizes the available models, methods, and key findings for CYP1A2, 2A6, 2C9, 2D6 and 3A4 isoenzymes.
Export Options
About this article
Cite this article as:
Arimoto Rieko, Computational Models for Predicting Interactions with Cytochrome p450 Enzyme, Current Topics in Medicinal Chemistry 2006; 6 (15) . https://dx.doi.org/10.2174/156802606778108951
DOI https://dx.doi.org/10.2174/156802606778108951 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Methods for Evaluating Sensory, Affective and Cognitive Disorders in Neuropathic Rodents
Current Neuropharmacology Recent Advances in Methods of Puerarin Biotransformation
Mini-Reviews in Medicinal Chemistry Review on Pharmacological and Phytochemical Prospects of Traditional Medicinal Plant: <i>Persicaria hydropiper</i> (Smartweed)
Current Topics in Medicinal Chemistry The Effect of First-in-Class Small Molecule RhoA Inhibitor, HL07, on the Phenylephrine-induced Artery Contraction
Current Pharmaceutical Design Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Preparation and Evaluation of Chitosan Loaded Naproxen Nanoparticles by Emulsion Interfacial Reaction Method
Drug Delivery Letters Multidrug Resistance Phenotype Mediated by the P-Glycoprotein-Like Transporter in Leishmania: A Search for Reversal Agents
Current Drug Targets Solid-Phase Synthesis of Oligosaccharide Drugs: A Review
Mini-Reviews in Medicinal Chemistry Formulation Development of Chitosan Coated Intra Nasal Ropinirole Nanoemulsion for Better Management Option of Parkinson: An In Vitro Ex Vivo Evaluation
Current Nanoscience Formulated Squalene for Food Related Applications
Recent Patents on Food, Nutrition & Agriculture Drug Repurposing Screen Identifies Novel Classes of Drugs with Anticancer Activity in Mantle Cell Lymphoma
Combinatorial Chemistry & High Throughput Screening MT1-MMP Activation of TGF-β Signaling Enables Intercellular Activation of an Epithelial-mesenchymal Transition Program in Cancer
Current Cancer Drug Targets Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents The Development of Copper Radiopharmaceuticals for Imaging and Therapy
Medicinal Chemistry The Use of Keratin in Biomedical Applications
Current Drug Targets Design, Synthesis and Antitumor Activity of Novel Cis-Furoquinoline Derivatives
Letters in Drug Design & Discovery Rapid Biosynthesis of Gold Nanoparticles Using Aqueous-ethanoic Leaf Extract of Heartleaf Moonseed: Characterization and Effect of pH on its Synthesis
Current Nanomaterials Preparation of 18β-glycyrrhetinic Acid Nano-Rods Using Emulsion- Solvent Evaporation Technique for Application in Cosmetics and Pharmaceuticals
Pharmaceutical Nanotechnology Xenicane Natural Products: Biological Activity and Total Synthesis
Current Pharmaceutical Design Carbon Based Sample Supports and Matrices for Laser Desorption/Ionization Mass Spectrometry
Recent Patents on Nanotechnology